Pharmaceutical company VIVUS (NASDAQ:VVUS) has been marketing its obesity drug, Qsymia, primarily to physicians -- but the drug's initial sales were far below what investors were expecting. Presumably under pressure to ramp up sales, VIVUS recently announced a consumer-targeted program that offers a two-week free trial to patients.

Is this the spark that VIVUS needs to get back on track, or will sales take another hit when Arena (NASDAQ:ARNA) and partner Eisai market their competing drug in early 2013?

In the following video, health care analysts Max Macaluso and Brenton Flynn discuss this new marketing approach and what VIVUS might need to do in order to increase revenue.

Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.